The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Neuroprotective effects of the antiparkinson drug Mucuna pruriens
Abstract
Mucuna pruriens possesses significantly higher antiparkinson activity compared with levodopa in the 6‐hydroxydopamine (6‐OHDA) lesioned rat model of Parkinson's disease. The present study evaluated the neurorestorative effect of Mucuna pruriens cotyledon powder on the nigrostriatal tract of 6‐OHDA lesioned rats. Mucuna pruriens cotyledon powder significantly increased the brain mitochondrial complex‐I activity but did not affect the total monoamine oxidase activity (in vitro). Unlike synthetic levodopa treatment, Mucuna pruriens cotyledon powder treatment significantly restored the endogenous levodopa, dopamine, norepinephrine and serotonin content in the substantia nigra. Nicotine adenine dinucleotide (NADH) and coenzyme Q‐10, that are shown to have a therapeutic benefit in Parkinson's disease, were present in the Mucuna pruriens cotyledon powder. Earlier studies showed that Mucuna pruriens treatment controls the symptoms of Parkinson's disease. This additional finding of a neurorestorative benefit by Mucuna pruriens cotyledon powder on the degenerating dopaminergic neurons in the substantia nigra may be due to increased complex‐I activity and the presence of NADH and coenzyme Q‐10. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326 · cited 1×
“Phase II studies of high dose synthetic coenzyme Q-10 suggested a retardation of Parkinson’s disease progression possibly through increased complexI activity (Shults et al., 1997).”
BackgroundExcitotoxicity and nitric oxide in parkinson's disease pathogenesis
Beal, M. F. (1998) · Annals of Neurology · doi:10.1002/ana.410440716 · Cited by 283
Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256 · cited 1×
“The antioxidant and neuroprotective activity of coenzyme Q-10 was also proved in animal models where coenzyme Q-10 administered orally prior to treatment with MPTP was found to protect the nigrostriatal dopaminergic system (Beal et al., 1998).”
BackgroundBirkmayer, J. G. D., Vrecko, C., Volc, D., & Birkmayer, W. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00018.x · Cited by 94
Altered redox state of platelet coenzyme Q 10 in Parkinson's disease
Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93
Birkmayer, W., Birkmayer, G. J. D., Vrecko, K., Mlekusch, W., Paletta, B., & Ott, E. (1989) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02263483 · Cited by 23
Cited by
Current Status of Herbal Drugs in India: An Overview
Vaidya, A. D. B., & Devasagayam, T. P. A. (2007) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.2007001 · Cited by 296
Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., Jeong, Y. J., Goh, S. H., Kim, C.-S., & Lee, K.-J. (2021) · Molecules · doi:10.3390/molecules26175327 · Cited by 182
Metadata
- Authors
- Manyam, B. V., Dhanasekaran, M., & Hare, T. A.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 18
- Issue
- 9
- Pages
- 706-712
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W2038647446
- Cited by
- 181
- References
- 7
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective effects of the antiparkinson drug Mucuna pruriens. https://app.cochat.ai/papers/10.1002/ptr.1514
- The paper
- Manyam, B. V., Dhanasekaran, M., & Hare, T. A. (2004). Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytotherapy Research. https://doi.org/10.1002/ptr.1514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.